Phenomenex to be Acquired by Danaher Corporation

Article

The Column

ColumnThe Column-10-24-2016
Volume 12
Issue 19
Pages: 5

Phenomenex has announced that it will be acquired by Danaher Corporation, a Fortune 150 science and technology company. Phenomenex will continue to operate as a standalone company, and will retain the Phenomenex brand, its personnel, and site locations.

Phenomenex (Torrance, California, USA) has announced that it will be acquired by Danaher Corporation (Washington, D.C., USA), a Fortune 150 science and technology company. Phenomenex will continue to operate as a standalone company, and will retain the Phenomenex brand, its personnel, and site locations.

“Phenomenex is a widely recognizable brand that we are proud to say is highly respected and well established as providing high-quality consumables to the scientific community worldwide,” said Fasha Mahjoor, CEO of Phenomenex. “Joining Danaher will allow us to maintain the high pace of innovation that our customers and international distributors have come to expect from us. This is our opportunity to further expand our R&D activities, benefit our customers with a more diversified product portfolio, and reinforce our market leadership.”

Phenomenex employees more than 700 people worldwide and provides support into 92 countries through direct and distributor channels.

“We are thrilled to have Phenomenex join Danaher’s life sciences portfolio of businesses, which include Sciex, Beckman Coulter Life Sciences, Pall, Leica Microsystems, and Molecular Devices,” said Dan Daniel, Executive Vice President of Danaher. “The Danaher Business System (DBS) has a strong track record of helping businesses rapidly scale operations and create long-term customer value. We look forward to supporting the Phenomenex team in leveraging DBS tools for growth and welcoming them to our Life Sciences team.”

The transaction is expected to close by late 2016. For more information, please visit www.phenomenex.com or www.danaher.com

Related Videos
Toby Astill | Image Credit: © Thermo Fisher Scientific
Robert Kennedy